City State Bank Gilead Sciences, Inc. Transaction History

City State Bank

$272 Million
Q3 2024

A detailed history of City State Bank transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, City State Bank holds 3,675 shares of GILD stock, worth $331,448. This represents 0.11% of its overall portfolio holdings.

Number of Shares

3,675

Previous 3,911 6.03%

Holding current value

$331,448

Previous $268,000 14.93%

% of portfolio

0.11%

Previous 0.11%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	SELL	$66.59 - $83.99 $15,715 - $19,821	-236 Reduced 6.03%	3,675 $308,000
Q2 2024 Jul 08, 2024	SELL	$63.15 - $72.88 $3,031 - $3,498	-48 Reduced 1.21%	3,911 $268,000
Q1 2024 Apr 11, 2024	SELL	$71.58 - $87.29 $1,717 - $2,094	-24 Reduced 0.6%	3,959 $290,000
Q4 2023 Jan 10, 2024	SELL	$73.27 - $83.09 $12,895 - $14,623	-176 Reduced 4.23%	3,983 $323,000
Q3 2023 Oct 16, 2023	SELL	$73.94 - $80.67 $1,774 - $1,936	-24 Reduced 0.57%	4,159 $312,000
Q2 2023 Jul 10, 2023	SELL	$76.01 - $86.7 $11,401 - $13,005	-150 Reduced 3.46%	4,183 $322,000
Q1 2023 Apr 10, 2023	SELL	$77.31 - $88.08 $11,519 - $13,123	-149 Reduced 3.32%	4,333 $360,000
Q4 2022 Jan 11, 2023	SELL	$62.32 - $89.47 $7,976 - $11,452	-128 Reduced 2.78%	4,482 $385,000
Q3 2022 Oct 24, 2022	BUY	$59.54 - $68.01 $11,610 - $13,261	195 Added 4.42%	4,610 $284,000
Q2 2022 Aug 22, 2022	BUY	$57.72 - $65.01 $4,906 - $5,525	85 Added 1.96%	4,415 $273,000
Q1 2022 Jun 01, 2022	BUY	$57.92 - $72.58 $26,353 - $33,023	455 Added 11.74%	4,330 $257,000
Q4 2021 Mar 23, 2022	SELL	$64.88 - $73.64 $31,791 - $36,083	-490 Reduced 11.23%	3,875 $281,000
Q4 2021 Mar 11, 2022	BUY	$64.88 - $73.64 $283,201 - $321,438	4,365 New	4,365 $270,000

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of City State Bank, based on Form 13F filings with the SEC.

News

Stay updated on City State Bank with notifications on news.

Account